Claims:

1. A composition comprising:
sirolimus present in an amount ranging from 1 wt% to 10 wt%, based on weight of the composition;
sucrose acetate isobutyrate (SAIB) present in an amount ranging from 0.1 wt% to 10 wt%, based on weight of the composition;
benzyl benzoate present in an amount ranging from 30 wt% to 60 wt%, based on weight of the composition;
ethanol present in an amount ranging from 1 wt% to 10 wt%, based on weight of the composition;
polyethylene glycol (PEG) present in an amount ranging from 30 wt% to 60 wt%, based on weight of the composition; and
vitamin E present in an amount ranging up to 5 wt%, based on weight of the composition.

2. The composition of claim 1, wherein:
the composition comprises from 1 wt% to 5 wt% of the sirolimus, based on weight of the composition.

3. The composition of any one of claims 1 and 2, wherein the benzyl benzoate is present in an amount ranging from 35 wt% to 45 wt%, based on weight of the composition.

4. The composition of any one of claims 1 to 3, wherein:
the ethanol is present in an amount ranging from 1 wt% to 7 wt%, based on weight of the composition.

5. The composition of any one of claims 1 to 4, wherein
the PEG is present in an amount ranging from 35 wt% to 50 wt%, based on weight of the composition, or from 40 wt% to 50 wt%, based on weight of the composition.

6. The composition of any one of claims 1 to 5, wherein (a) the vitamin E is present in an amount ranging from 0.5 wt% to 2 wt%, based on weight of the composition; or (b) the composition has a weight ratio of SAIB:vitamin E ranging from 0.5 to 10.

7. The composition of claim 1, wherein:

(A) the vitamin E is present in an amount ranging from 0.1 wt% to 5 wt%, based on weight of the composition;

and preferably wherein:

(B) the sirolimus is present in an amount ranging from 1 wt% to 5 wt%, based on weight of the composition;
the benzyl benzoate is present in an amount ranging from 30 wt% to 45 wt%, based on weight of the composition;
the PEG is present in an amount ranging from 40 wt% to 50 wt%, based on weight of the composition; and
the vitamin E is present in an amount ranging from 0.5 wt% to 2 wt%, based on weight of the composition;

and more preferably wherein:

(C) the composition consists essentially of:
sirolimus in an amount ranging from 1 wt% to 5 wt%, based on weight of the composition;
SAIB in an amount ranging from 0.1 wt% to 10 wt%, based on weight of the composition;
benzyl benzoate in an amount ranging from 30 wt% to 45 wt%, based on weight of the composition;
ethanol in an amount ranging from 1 wt% to 10 wt%, based on weight of the composition;

PEG400 in an amount ranging from 40 wt% to 50 wt%, based on weight of the composition; and

vitamin E in an amount ranging from 0.5 wt% to 2 wt%, based on weight of the composition.

8. The composition of claim 1, the composition consisting essentially of:

sirolimus in an amount ranging from 1 wt% to 5 wt%, based on weight of the composition;

SAIB in an amount not exceeding 10 wt%, based on weight of the composition;

benzyl benzoate;

ethanol and PEG400; and

vitamin E in an amount ranging from 0.5 wt% to 2 wt%, wherein a weight ratio of SAIB to vitamin E exceeds 0.5.

9. The composition of any one of claims 1 to 8, wherein the composition is pharmaceutically acceptable, and preferably wherein the composition is formulated for injection.

10. The composition of claim 1, which comprises

sirolimus in an amount of about 3 wt%, based on weight of the composition

SAIB in an amount of about 1 wt%, based on weight of the composition;

benzyl benzoate in an amount of about 43.7 wt%, based on weight of the composition;

ethanol in an amount of about 4.8 wt%, based on weight of the composition;

PEG400 present in an amount of about 46.5 wt%, based on weight of the composition; and

vitamin E in an amount of about 1 wt%, based on weight of the composition.

11. A composition as defined in any one of claims 1 to 10 for use as a medicament.

12. A composition as defined in any one of claims 1 to 10 for use in treatment of an eye condition, and preferably wherein the eye condition comprises uveitis, diabetic macular edema, or wet age-related macular degeneration.